NCT04379999View on ClinicalTrials.gov

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions
Lynch Syndrome
Interventions
DRUG

Atorvastatin 20mg

No history of colorectal cancer and no colorectal adenomas within 5 years.

DRUG

Atorvastatin 20mg AND Aspirin 325 mg

History of colorectal cancer and/or history of colorectal adenomas within 5 years.

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

Prevent Cancer Foundation

OTHER

lead

Fox Chase Cancer Center

OTHER

NCT04379999 - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome | Biotech Hunter | Biotech Hunter